OBI.L LSE
Ondine Biomedical Inc.
1W: -9.3%
1M: -17.0%
3M: -36.7%
YTD: +5.4%
1Y: -40.9%
3Y: -33.9%
£9.75 ($0.13)
+0.00 (+0.00%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Cash Flow Trends
Operating Cash Flow
-$15M
-13.5% ▼
Capital Expenditures
$10K
+94.4% ▲
5Y CAGR: -21.2%
Free Cash Flow
-$16M
-12.1% ▼
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
$7M
+167.0% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$16M | -$50M | -$19M | -$14M | -$19M |
| Depreciation & Amort. | $1M | $514K | $493K | $587K | $565K |
| Stock-Based Comp. | $8M | $4M | $1M | $640K | $1M |
| Change in Working Capital | -$361K | $131K | $102K | -$298K | $2M |
| Other Non-Cash Items | $532K | $1M | $987K | -$170K | -$86K |
| Operating Cash Flow | -$6M | -$13M | -$16M | -$14M | -$15M |
| — Investing Activities — | |||||
| Capital Expenditures | -$99K | -$77K | -$311K | -$177K | -$10K |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 |
| Investment Purchases | $0 | $0 | $0 | $0 | $0 |
| Investment Sales | $0 | $0 | $0 | $0 | $0 |
| Other Investing | $3M | $0 | $0 | $0 | $0 |
| Investing Cash Flow | $3M | -$77K | -$311K | -$177K | -$10K |
| — Financing Activities — | |||||
| Net Debt Issuance | $4M | $6M | $0 | -$40K | $1M |
| Stock Repurchased | $0 | -$799K | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | -$3M | -$1M | -$275K | -$1M | -$2M |
| Financing Cash Flow | $4M | $42M | -$275K | $4M | $22M |
| Net Change in Cash | $320K | $29M | -$17M | -$10M | $7M |
| Cash End of Period | $626K | $30M | $13M | $3M | $10M |
| Free Cash Flow | -$6M | -$13M | -$17M | -$14M | -$16M |